Viral Vertigo

Langreth, Robert
November 2007
Forbes Asia;11/26/2007, Vol. 3 Issue 20, p102
The article reports on the effort of Vertex Pharmaceuticals to devise a new drug to combat hepatitis C. Vertex has a drug in the pipeline called telaprevir that it hopes will be the first in a new generation of hep C treatments. Telaprevir is a protease inhibitor that attacks the virus directly and blocks its replication. Vertex has already surmounted an array of problems since it started working on hepatitis C in 1993. Vertex executive John Thomson, says it became clear what a remarkable challenge designing a protease inhibitor would be.


Related Articles

  • Vertex: dipping into the non-responders pool.  // PharmaWatch: Monthly Review;Nov2005, Vol. 4 Issue 11, p34 

    The article reports that Vertex Pharmaceuticals Inc. has unveiled encouraging results from a phase lb trial evaluating its vaccine, VX-950 in hepatitis C. Hepatitis C virus (HCV) protease inhibitors led by VX-950 are currently perceived as the most promising drug in the battle against chronic...

  • COMPANY SPOTLIGHT - Vertex Pharmaceuticals.  // PharmaWatch: Monthly Review;Jan2006, Vol. 5 Issue 1, p46 

    This article reports on the phase II clinical trial for VX-950, an investigational oral hepatitis C vaccine initiated by Vertex Pharmaceuticals Inc. The purpose of this trial is to study the treatment in combination with two existing therapies, pegylated interferon and ribavirin. Vertex is...

  • Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful.  // Biomedical Market Newsletter;5/21/2011, p755 

    The article reports that the phase 3 result in Telaprevir-Based Therapy study of Vertex Pharmaceuticals Inc. shows improvement in SVR (viral cure) rates in people with prior unsuccessful treatment for Hepatitis C in Berlin, Germany. JW Goethe University Hospital professor Stefan Zeuzem noted...

  • Vertex Hepatitis Drug WinsUS Panel Support.  // Clinical Infectious Diseases;7/15/2011, Vol. 53 Issue 2, preceding p107 

    The article reports that Vertex Pharmaceuticals Inc. has won an approval by an advisory panel of the U.S. for a new hepatitis C drug which almost increases the chances of curing the liver-destroying disease.

  • Hepatitis C: A "silent killer".  // Pharmacy Today;Aug2012, Vol. 18 Issue 8, p3 

    The article reports on the prevalence of hepatitis C in the U.S., wherein Vertex Pharmaceuticals Inc. has launched Better to Know C website, located at www.bettertoknowc.com, a website regarding the information on hepatitis C.

  • VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.  // Worldwide Biotech;Aug2004, Vol. 16 Issue 8, p6 

    Reports on the agreement between Vertex Pharmaceuticals Inc. and Mitsubishi Pharma Corp. to develop and commercialize VX-950, Vertex's investigational oral protease inhibitor for the treatment of hepatitis C virus. Payments to be given by Mitsubishi to Vertex as part of the agreement; Statement...

  • Vertex Aims for $320M Offering to Push Telaprevir.  // Bioworld Week;2/23/2009, Vol. 17 Issue 8, p1 

    The article reports on the plan of Vertex Pharmaceuticals Inc. to sell its shares at around $32 for the development and commercialization of teleprevir for hepatitis C virus and VX-770. It states that the fund will help the firm through the anticipated 2011 launch of teleprevir. According to Ian...

  • Telaprevir.  // Drugs in R&D;2010, Vol. 10 Issue 3, p179 

    Telaprevir (LY 570310; LY-570310; LY570310;MP 424;MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. It is being developed by Vertex Pharmaceuticals and its licensees for the treatment of HCV infections and has recently been...

  • Telaprevir Looks Ever-Better, But Don't Discount Boceprevir. Morrison, Trista // BioWorld Insight;8/16/2010, Vol. 18 Issue 33, p3 

    The article reports on the competition in the development of effective pharmacology for hepatitis C virus (HCV). Accordingly, Vertex Pharmaceuticals Inc. has reported a 75 percent HCV cure rate from the protease inhibitor telaprevir, while the boceprevir from Merck & Co. Inc. has reported a 66...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics